AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...
AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...
As if a limited initial FDA approval was not bad enough, AstraZeneca ... in this subgroup. The drug’s initial FDA nod in HR-positive, HER2-negative breast cancer, obtained in November, is ...
AstraZeneca shares slumped after its key lung-cancer drug trial failed necessary targets that could risk U.S. Food & Drug Administration approval in the coming weeks. AstraZeneca shares slid 5% to ...
A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates. The results from the trial showed that the ...
London-listed AstraZeneca (AZN.L), opens new tab shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not ...
Also Read: AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities. Dato-DXd is an engineered TROP2-directed DXd antibody-drug conjugate ... on Lung Cancer (WCLC), the ...
The company’s datopotamab ... lung cancer conference in San Diego on Monday. The drug was developed with Japanese company Daiichi Sankyo, with which AstraZeneca has also developed its breast ...
(RTTNews) - AstraZeneca ... small cell lung cancer, patients only survive for about one year. The TROPION-Lung01 Phase III trial evaluated AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan ...